Tara Chang

Tara I. Chang, MD, MS, Associate Professor and Chief, Division of Nephrology, Department of Medicine, Stanford University School of Medicine

Research Description: Diabetes mellitus and hypertension are two major risk factors for both cardiovascular disease and chronic kidney disease (CKD), yet patients with significant CKD are often excluded from studies in these areas. Dr. Chang’s research uses advanced epidemiological methods to investigate the management of diabetes mellitus, hypertension and cardiovascular disease in CKD to ultimately improve their clinical outcomes. In addition to collaborating with several SDRC members, Dr. Chang was Co-National Leader in the Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy (CREDENCE).

Selected relevant publications (Stanford DRC Members in BOLD):

  1. Sarraju, A, L JW, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KW. Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial. Am Heart J 2021 233: 141-148. PMID 3358942. 

  2. Ye N, Jardine MJ, Oshima M, Hockham C, Heerspink HJL, Agarwal R, Bakris G, Schutte AE, Arnott C, Chang TI, Gorriz JL, Cannon CP, Charytan DM, de Zeeuw D, Levin A, Mahaffey KW, Neal B, Pollock C, Wheeler DC, Di Tanna GL, Cheng H, Perkovic V, Neuen BL. Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: Insights from the CREDENCE trial.  Circulation 2021, Feb 8. doi: 10.1161/CIRCULATIONAHA. 120.048740. PMID: 33552616 

  3. Wang KM, Li JW, Bhalla V, Jardine MJ, Nea B, de Zeeuw D, Fulcher G, Perkovic V, Mahaffey KW, Chang TI. Canagliflozin, serum magnesium and cardiovascular outcomes – Analysis from the CANVAS program. Endocrinology, Diabetes and Metabolism 2021, in press. 

  4. Kim SH, Chang TI, Mahaffey KW. A Call for a New Paradigm for Diabetes Care in the Era of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i). Cardiol Ther. 2020 Dec;9(2):219-225. doi: 10.1007/s40119-020-00190-7. PMID: 32661684; PMCID: PMC7584703. 

  5. Jakher H, Chang TI, Tan M, Mahaffey KW. Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes Metab Syndr Obes. 2019 Feb 1;12:209-215. doi: 10.2147/DMSO.S184437. PMID: 30787627; PMCID: PMC6363491. 

  6. Haase SB, Chang S, Schiller B, Chertow GM, Chang TI. Antihypertensive medication withholding practices in hemodialysis: A survey study of patients and providers. Hemodial Int. 2018 Jul;22(3):415-418. doi: 10.1111/hdi.12640. PMID: 29436151; PMCID: PMC6211846.